Ventas is a healthcare REIT growing revenue at 22% annually with 570% free cash flow conversion relative to net income, but the stock offers only 4.4% upside to analyst targets, carries a below-average business quality score of 4.2, and has a dividend flagged as potentially yield-trap territory — limiting the near-term appeal despite solid operating momentum.
Thesis pillars
- Dividend Yield Trap Risk→Stable
- Exceptional Free Cash Flow Conversion→Stable
- Industry Growth Leader→Stable
- +1 more pillar — see the Why tab for full reasoning
Ventas, Inc. (VTR) Stock Analysis
Real Estate · REIT - Healthcare Facilities
Sell if holding. Analyst target reached at $92.52 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.4% away).
Ventas, Inc. owns 1,409 properties across three segments — senior housing operating (SHOP, 49.4% of NOI), outpatient medical and research (OM&R, 24.7%), and triple-net leased healthcare (NNN, 24.6%) — in the U.S., Canada, and the U.K. The company earns $2.4 billion in annual NOI... Read more
Sell if holding. Analyst target reached at $92.52 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 25d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Ventas, Inc.
About Ventas, Inc.
Ventas's 1,409-property portfolio generated $2.4 billion in total NOI for 2025, concentrated in three healthcare-aligned property types: 752 senior housing communities in the SHOP segment (49.4% of NOI), 409 outpatient medical and research buildings in the OM&R segment (24.7%), and 213 triple-net leased healthcare facilities in the NNN segment (24.6%). California was the only state accounting for more than 10% of total revenues; Canada contributed 9.5% and the United Kingdom 1.2%.
Ventas earns revenue through three distinct structures. In the SHOP segment, the company participates directly in the financial performance of senior housing communities managed by 39 third-party operators; Atria Senior Living managed properties representing 17.7% of total 2025 NOI, Sunrise Senior Living 6.8%, and Le Groupe Maurice 5.6%. Managers receive annual fees calculated on revenue and NOI metrics with incentive provisions for performance targets. The OM&R segment leases outpatient medical buildings and research centers to health systems, universities, and biotechnology companies under fixed-term gross or modified leases; these properties generate stable NOI but expose the company to tenant credit risk without direct operational participation. The NNN segment deploys absolute-net leases to hospital operators including Ardent Health Partners (6.4% of total NOI) and Kindred Healthcare (5.8%), with rent escalators tied to the CPI or facility revenue metrics. The capital structure includes both secured and unsecured debt, and the 10-K identifies rising interest rates as a potential headwind to refinancing economics and acquisition capacity.
Show full overview
The company's exposure to government funding represents a distinct risk not present in other REIT property types. University and academic medical center tenants in the OM&R segment may depend on NIH grants to partially fund rent payments; the 10-K notes that in 2025 the U.S. administration adopted substantial policy changes affecting research funding, which could impair these tenants' ability to meet lease obligations. Meanwhile, the Brookdale Senior Living lease portfolio — which accounted for 6.2% of total NOI in 2025 largely due to transitional properties — is expected to shrink materially from 2026 forward, as 42 properties converted to SHOP during 2025 and 3 more converted on January 1, 2026.
See also: Real Estate · REIT - Healthcare Facilities
From Ventas, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-07-06Recent Developments — Ventas, Inc.
Latest news
- NEWS Ventas (VTR) Stock: Downside Risk Review (-2.14%) 2026-04-22 - Elite Trading Signals - Cổng thông tin điện tử Tỉnh Sơn L — Cổng thông tin điện tử Tỉnh Sơn La neutral
- NEWS Ventas (VTR) Stock: Downside Risk Review (-2.14%) 2026-04-22 - Bollinger Bands - Cổng thông tin điện tử tỉnh Lào Cai — Cổng thông tin điện tử tỉnh Lào Cai negative
- NEWS Ventas Inc Stock (US9227931050): Analyst Targets And Valuation Back In Focus After Recent Rally - AD HOC NEWS — AD HOC NEWS neutral
- NEWS Is Ventas Inc (VTR) Overvalued After 3.6% Rally? GF Value Says O - GuruFocus — GuruFocus positive
- NEWS Ventas Inc (VTR) Stock Down 3.0% but Still Overvalued -- GF Score: 81/100 - GuruFocus — GuruFocus negative
Generated 2026-07-06T06:50:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWTenantAtria Senior Living18%10-K Item 1: 'Atria Senior Living, Inc.| 17.7 | %'
- LOWGeographicCalifornia10-K Item 1: 'properties in only one state (California) accounting for more than 10% of our total revenues for the year ended December 31, 2025'
Material Events(8-K, last 90d)
- 2026-05-15Item 5.02MEDIUMEVP Peter J. Bulgarelli (Outpatient Medical & Research; President/CEO of Lillibridge Healthcare) retired May 1, 2026. Separation agreement entered May 12, 2026 providing prorated 2026 bonus. Retirement previously disclosed; no successor named for the EVP role.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $92.52 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $88.66. Score 5.4/10, moderate confidence.
Take-profit target: $91.00 (-1.6% upside). Prior stop was $88.66. Stop-loss: $88.66.
Analyst target reached - limited upside remaining; Near 52-week high (0.4% away); Euphoria warning: extreme positivity (+1.00) + overbought RSI 79.
Ventas, Inc. trades at a P/E of 168.2 (forward 109.3). TrendMatrix value score: 3.7/10. Verdict: Sell.
25 analysts cover VTR with a consensus score of 4.1/5. Average price target: $97.
What does Ventas, Inc. do?Ventas, Inc. owns 1,409 properties across three segments — senior housing operating (SHOP, 49.4% of NOI), outpatient...
Ventas, Inc. owns 1,409 properties across three segments — senior housing operating (SHOP, 49.4% of NOI), outpatient medical and research (OM&R, 24.7%), and triple-net leased healthcare (NNN, 24.6%) — in the U.S., Canada, and the U.K. The company earns $2.4 billion in annual NOI through direct SHOP operations managed by 39 third-party operators, fixed triple-net leases, and multi-tenant medical building leases.